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OSRx, particularly in those women diagnosed with osteopenia
and/or osteoporosis according to their test results.
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OBJECTIVES: Patients and physicians are sometimes asked to
ﬁll in questionnaires concerning clinical events and resource util-
isation such as tests and investigations. This study analyses dif-
ferences in reporting of diagnostic tests and clinical events by a
matched sample of doctors and patients in the management of
osteoporosis in ﬁve countries. METHODS: The data are drawn
from the Disease Speciﬁc Programme in Osteoporosis, which col-
lected information about osteoporosis management from both
doctors and patients. The study included 7349 patients (aged
50–80 with osteoporosis or suspected osteoporosis), treated by
709 doctors in France, UK, Germany, Italy, USA. For each doctor
record, patients were asked to ﬁll out a self-completion ques-
tionnaire. 2646 matched patient self-completion records were
obtained. Key data items collected from both doctors and
patients were X-rays, bone mineral density (BMD) scanning, and
fractures. Differences between matched physician and patient
responses were tested using the Fisher Exact test. RESULTS:
Patients were signiﬁcantly more likely to recall X-rays than
doctors (41.2% vs. 33.8%, p < 0.01). This difference was sig-
niﬁcant in each country except Italy and Germany, although
patients still reported higher levels of testing. No signiﬁcant dif-
ferences were found for BMD scanning other than the UK, where
patients reported a higher level of testing (65.0% vs. 44.0%, 
p < 0.01). Patients were less likely to report fractures (30.0% vs.
36.4%, p < 0.01). Statistically signiﬁcant differences were
observed in all countries except the USA. CONCLUSIONS: This
study demonstrates differences between physicians and patients
in terms of both resource use and events. Patients reported more
tests but less fractures than doctors. These ﬁndings have impli-
cations for economic evaluations. Evidence from patients must
be treated with caution, due to potential problems of recall bias
and/or misunderstanding of tests and events. The importance 
of using hard evidence for retrospective analysis cannot be 
overstated.
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OBJECTIVE: More than 1.5 million fractures occur due to
osteoporosis each year. This study examines the characteristics
of osteoporosis patients who incur an osteoporosis-related frac-
ture compared to osteoporosis patients who do not incur frac-
ture and estimates the economic burden associated with the
illness. METHODS: The study sample consisted of patients with
an osteoporosis diagnosis (733.0x) between January 1, 1998 and
December 31, 2000. Osteoporosis patients with both an osteo-
porosis diagnosis and a related fracture were classiﬁed as having
severe osteoporosis, all other osteoporosis patients were classi-
ﬁed as Non-Severe. Annual utilization and expenditures for the
Severe cohort were compared to the Non-severe cohort, as well
as to a group of patients without osteoporosis (Controls)
matched 3 :1 to the Severe osteoporosis cohort based on age,
gender, region, health plan type, and length of enrollment.
Patients with malignant neoplasm, carcinoma, or Paget’s disease
of bone were excluded from all groups. Exponential conditional
mean models were used to compute regression-adjusted total
expenditures across the groups and the differences in adjusted
expenditures were used to generate the economic burden of
illness estimates. RESULTS: Patients with Severe osteoporosis
incurred twice the amount of overall health care expenditures in
the study period compared to Non-Severe osteoporosis patients
and nearly three times that of the control group. Approximately
25% of the overall health care expenditures for the severe group
were osteoporosis-related expenditures, leading to the conclu-
sion that comorbid conditions in patients with severe osteo-
porosis contribute signiﬁcantly to overall health care costs. Some
of these comorbidity-related costs are likely due to pain-related
disorders, which occurred signiﬁcantly more frequently than in
the Non-Severe and Control cohorts. CONCLUSIONS: Osteo-
porosis-related expenditures, particularly those related to frac-
ture, were substantial. However, non-osteoporosis-related
expenditures to treat comorbid conditions constituted 75% of
the overall health care costs incurred in the year after an osteo-
porosis-related fracture and warrant further investigation.
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OBJECTIVES: To examine the cost and effectiveness of long-
term hormone replacement therapy (HRT) in healthy post-
menopausal women for preventing osteoporosis. Although HRT
has been widely used for osteoporosis prevention, previous
studies on its cost-effectiveness showed controversial results.
Recently, the Women’s Health Initiative (WHI) study found sig-
niﬁcant clinical risks with HRT. METHODS: From a societal
perspective, resource consumption, incidence rates and relative
risks were collected for the following diseases in HRT-treated
and HRT-naïve women: breast cancer, colorectal cancer, CHD,
stroke, pulmonary embolism, dementia, and bone fractures.
Besides the WHI results, cost, utility and other clinical data were
from published literature, CDC vital statistics databases, and
SEER cancer statistics. Using a 3% annual discount rate, pro-
jected lifetime costs and quality-adjusted life years (QALYs) were
estimated by DEALE and backward induction methods and com-
pared in women with HRT vs. without HRT for each age group
at 5-year intervals. RESULTS: Under the base case assumptions,
HRT increased average lifetime treatment costs ($20,753 for
non-HRT group vs. $31,941 for HRT group), and yet reduced
average discounted quality adjusted life expectancy (10.18 years
for non-HRT group vs. 5.87 years for HRT group), indicating
that HRT use is an inferior strategy. These negative results were
largely attributed to the net increased risks in breast cancer and
CHD due to HRT. As age increased from 50 to 90, the incre-
mental costs increased from $2221 to $18,988, and loss in
QALYs decreased from 10.8 to 0.44 years. The model results
were relatively insensitive to reasonable parameter changes.
CONCLUSIONS: For healthy postmenopausal women, long-
term HRT to prevent osteoporosis raises overall treatment costs
